{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041586","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.640143+00:00","generated_at":"2026-06-11T14:38:35.215325+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aeglea closes Spyre asset acquisition, raises $210M, sells pegzilarginase, reports Q2 loss","bullets":["Acquired Spyre's IBD pipeline (α4β7 and TL1A) for stock; raised $210M gross via Series A preferred private placement.","Sold pegzilarginase rights to Immedica for $15M upfront + up to $100M milestones; net proceeds to CVR holders.","Cash and equivalents $236.7M at June 30, including $210M financing; Q2 net loss $217.1M from acquisition-related charges.","Net loss includes $130.5M acquired IPR&D expense and $58.2M forward contract liability expense.","Expect SPY001 FIH study in H1 2024; SPY002 FIH study in H2 2024; healthy volunteer data by end-2024 / H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041586","json":"https://secwatch.observer/filing/0000950170-23-041586.json","markdown":"https://secwatch.observer/filing/0000950170-23-041586.md","text":"https://secwatch.observer/filing/0000950170-23-041586.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000095017023041586/0000950170-23-041586-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000095017023041586/agle-20230811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T14:38:35.215325+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"98ddc0ea3f01ad5f1379890e9a47ec1b72b9964d","claim":"Spyre Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 11, 2023, Aeglea BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017023041586/0000950170-23-041586-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}